LeMaitre Vascular (NASDAQ:LMAT) Issues Q4 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its fourth quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.750-0.81 for the period, compared to the consensus estimate of 0.790. The company issued revenue guidance of $71.1 million-$73.1 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wells Fargo & Company lowered their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a report on Wednesday. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Citizens Jmp upped their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Stock Up 1.5%

LMAT stock traded up $1.20 during mid-day trading on Thursday, reaching $80.19. The company had a trading volume of 302,587 shares, compared to its average volume of 268,554. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 28.14, a price-to-earnings-growth ratio of 2.94 and a beta of 0.53. The firm has a fifty day simple moving average of $97.08 and a 200 day simple moving average of $99.99. LeMaitre Vascular has a fifty-two week low of $78.65 and a fifty-two week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.90%. The firm had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. During the same quarter in the previous year, the business posted $0.60 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 9.6% compared to the same quarter last year. Analysts forecast that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be issued a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $1.00 annualized dividend and a dividend yield of 1.2%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.90%.

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the transaction, the insider owned 3,749 shares in the company, valued at $401,143. This trade represents a 43.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.40% of the stock is currently owned by insiders.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, while EPS rose to $0.74 from $0.60 a year earlier. The company also declared a quarterly dividend of $0.25 per share, equivalent to an approximately 1.1% annualized yield. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: Analyst sentiment has become more cautious. Wells Fargo lowered its price target from $104 to $94 while maintaining an Equal Weight rating, and Barrington Research downgraded the shares from Outperform to Market Perform. The average analyst view is now Hold. LeMaitre receives average Hold rating
• Negative Sentiment: Q2 EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million came in below the $71.47 million forecast. The earnings shortfall indicates that revenue growth has not translated into results as strongly as investors expected. LeMaitre Q2 earnings and revenues lag estimates
• Negative Sentiment: Management reduced its outlook: third-quarter EPS guidance of $0.66-$0.71 and revenue guidance of $66.3-$68.3 million are below consensus estimates of $0.73 and $69.0 million. Full-year EPS guidance of $2.84-$2.94 and revenue guidance of $274.3-$278.3 million also trail consensus forecasts of $3.00 and $279.9 million. LeMaitre guidance and financial results
• Negative Sentiment: The combination of missed quarterly estimates, lowered guidance, analyst downgrades and a new 12-month low is driving the bearish reaction in LMAT despite continued year-over-year growth and a strong balance-sheet profile. LeMaitre reaches new 12-month low

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors have recently modified their holdings of LMAT. Goldman Sachs Group Inc. increased its stake in LeMaitre Vascular by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after buying an additional 231,157 shares during the period. Millennium Management LLC increased its stake in shares of LeMaitre Vascular by 119.8% during the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after acquiring an additional 115,141 shares during the period. First Trust Advisors LP raised its holdings in LeMaitre Vascular by 13.4% during the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after purchasing an additional 111,193 shares in the last quarter. Geode Capital Management LLC lifted its position in LeMaitre Vascular by 20.1% in the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after purchasing an additional 105,921 shares during the period. Finally, Algert Global LLC boosted its holdings in LeMaitre Vascular by 356.3% in the 3rd quarter. Algert Global LLC now owns 66,268 shares of the medical instruments supplier’s stock valued at $5,799,000 after purchasing an additional 51,744 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.